arrow
C

Chang Lu

Zunyi Medical University
H指数:8
被引数:189

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System Disease

PEARL:一项关于洛拉替尼在ALK重排非小细胞肺癌合并中枢神经系统疾病患者中的多中心II期研究

2024-12-040
PRE
Redoxhigh phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma

KEAP1/STK11/SMARCA4/NRF2突变介导的Redoxhigh表型减少了组织驻留的记忆性CD8 T细胞并减弱了肺腺癌的免疫治疗效果

2024-04-092
OA
Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancer

EGFR突变非小细胞肺癌患者肠道菌群分布特征及动态变化与免疫治疗疗效的相关性

2024-04-023
OAAI
Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial
2023-10-014
OAAI
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial
2023-07-2421
PRE